EIC Summit 2026: Four life science giants meet 16 EIC-backed startups to scope pilots and partnerships
- ›At the EIC Summit 2026 in Brussels the EIC hosted a Life Sciences Multi-Corporate Day that matched 16 EIC-backed start-ups with AstraZeneca, Bayer, Chiesi and Coloplast.
- ›The start-ups, selected from nine countries, pitched after receiving targeted coaching and entered structured one-to-one meetings with senior corporate decision makers and technical experts.
- ›The EIC will provide follow-up support and Dealmaker assistance over the next six months to help turn conversations into scoped pilots and commercial agreements.
- ›The event sat inside the wider EIC Summit and included a keynote and fireside chat on venture clienting and corporate-startup collaboration.
- ›The exercise showcases how the EIC Corporate Partnership Programme channels pre-vetted deep tech to industry but the path from pitch to pilot will face regulatory, integration and commercial hurdles.
EIC Summit 2026 Multi-Corporate Day on Life Sciences
On 3 June 2026 the European Innovation Council convened a sector-specific matchmaking day inside its flagship EIC Summit in Brussels. The EIC brought four large life science corporations AstraZeneca, Bayer, Chiesi and Coloplast together with 16 EIC-funded start-ups from nine countries. Siemens Healthineers and Sanofi attended as observers. The aim was practical. Startups presented focused solutions in therapeutics diagnostics and patient care and then moved into structured one-to-one meetings with corporate technical and commercial leads to explore pilots co-development and commercial pathways.
Format and participants
Selected start-ups were pre-chosen by the corporate partners and received intensive preparation from the EIC. Preparation included a group briefing with corporate partners one-to-one business coaching pitch dry runs and business proposal reviews. The in-person day combined two pitching rounds with scheduled one-to-one meetings intended to accelerate conversations toward concrete pilot or partnership scopes. Senior corporate attendees included Robert Roth from AstraZeneca BioVentureHub Ruth Shah from Bayer Co.Lab Berlin Fabrizio Conicella from Chiesi and Hanne Jensen from Coloplast. EIC representatives Stéphane Ouaki and Manuel Mendigutía participated and stressed the strategic aim of connecting high potential innovators with companies that can scale their technologies. Observers included Sven Jager from Sanofi and René Pompl from Siemens Healthineers.
What the corporations were looking for
Each corporate partner brought specific needs and strategic priorities. AstraZeneca targeted next generation therapeutics and drug discovery tools including new modalities drug delivery systems early stage discovery technologies and greener chemistry. Bayer focused on transformative drug development including drug delivery expanding the druggable space and applying AI in discovery. Chiesi concentrated on respiratory and neonatal care under its AIR and CARE pillars with a cross cutting emphasis on health equity and access. Coloplast sought non pharmacological solutions for bowel and gut health bladder and urinary health and stoma care and surgical therapeutics. For corporate R and D teams the value claim was time efficiency. Pre vetted and prepared companies enabled rapid technical discussions about integration regulatory hurdles and deployment.
The 16 EIC-backed innovators and their technologies
The cohort included companies working across diagnostics therapeutics medical devices computational modelling AI and advanced materials. Below is a concise catalogue of the participants and their primary proposition.
| Company | Country | Technology or focus |
| AINDO | Italy | Generative AI platform that produces synthetic clinical datasets mirroring real world data without personal information for analysis sharing and reuse |
| BESTHEALTH4U | Portugal | Bio inspired skin friendly interfaces for stoma care aiming to reduce reliance on conventional adhesives and protect peristomal skin |
| BIOMODICS | Denmark | Biomimetic zwitterionic polymers for medical device surfaces tunable drug delivery including urinary catheter platform and blood brain barrier crossing nanoparticles |
| BIOPSENSE | Finland | Point of care cartridge that integrates plasma separation cell free DNA extraction quantification and stabilisation to standardise liquid biopsy workflows |
| ELEM BIOTECH | Spain | In silico human cardiac simulation platform using Virtual Human Trials to predict cardiac safety and efficacy across diverse patient phenotypes |
| EVERSENS | Spain | Integrated platform measuring clinical grade exhaled biomarkers with environmental data and AI analytics for predictive respiratory care at home |
| IKTOS | France | Autonomous drug discovery platform combining generative AI retrosynthesis planning and robotic synthesis to close the design make test analyse loop |
| INNOCON MEDICAL | Denmark | Dorsal genital nerve stimulation device for at home treatment of overactive bladder and bowel dysfunction as a lower cost alternative to implants |
| INTEGRA THERAPEUTICS | Spain | FiCAT gene writing platform enabling precise virus free insertion of large DNA fragments for next generation cell and gene therapies |
| LINCBIOTECH | Spain | Lysosome Targeting Degrader platform built from recombinant fusion proteins for selective removal of extracellular and membrane bound proteins |
| NEOVIVUM TECHNOLOGIES | Serbia | AI powered computational biology platform that predicts patient specific drug outcomes by modelling the tumour microenvironment |
| QUBIT PHARMACEUTICALS | France | ATLAS platform combining quantum science physics based modelling and AI to predict potency selectivity toxicity and explore cryptic allosteric pockets |
| SCIENTA LAB | France | EVA precision immunology model trained on over 200 000 biosamples across 60 plus immune mediated diseases for target identification and validation |
| SEQUENTIA BIOTECH | Spain | MICK platform that uses microbiome analysis to characterise dysbiosis and track gut health for data driven stoma and continence care |
| PREEMIE by TELLSPEC | United Kingdom | Federated learning neonatal intelligence ecosystem predicting life threatening neonatal conditions and length of stay risk without raw patient data leaving firewalls |
| TRINCE | Belgium | LumiPore photoporation platform using laser activated nanoparticles to deliver molecules into hard to transfect cells gently and efficiently |
Technology concepts explained
Follow up support and next steps
The EIC said it will continue to support the start ups and corporate partners for six months after the sessions with dedicated follow up aimed at translating discussions into scoped trials pilot agreements or commercial deals. The programme will offer Dealmaker Support to help finalise agreements and will monitor progress to capture tangible business impact. Participants described the day as a rare chance to reach decision makers who are otherwise difficult to access although several founders and corporate leads acknowledged that these conversations are only the start of longer validation regulatory and commercial processes.
Corporate partners praised the pre selection and preparation. Ruth Shah from Bayer said that receiving a pre selected well prepared group of companies allowed Bayer to get straight to technical details. Hanne Jensen from Coloplast emphasised the quality of exchanges and the speed at which the conversations moved to practical questions. Founders welcomed the access and the concrete feedback while warning that pilots will need careful scoping before commitments are made.
What to watch and realistic limitations
The Multi Corporate Day is an efficient discovery mechanism yet it is important to be pragmatic. For health and life science innovations the route from a successful pitch to a deployed pilot can be slowed by clinical validation regulatory approval interoperability with existing care pathways and commercial procurement cycles. Technical integration work can require months of engineering and clinical studies often stretching beyond the six month follow up window. Intellectual property commercialization terms and liability allocation also take time to negotiate. The EIC model shortens discovery and initial vetting but does not remove these fundamental constraints.
For policymakers and ecosystem builders the event illustrates progress in connecting deep tech SMEs with corporate absorptive capacity. The EIC Corporate Partnership Programme has run a number of corporate days since 2017 and reports measurable outcomes from past activities. Those historical metrics provide context that the current initiative builds on but they do not guarantee individual deal flow for this cohort.
| Metric | Programme claim or history | Caveat |
| Corporate Day and Multi Corporate Day activity | 91 events organised since 2017 with thousands of one to one meetings | Event numbers show scale but not uniform deal conversion rates across sectors |
| One to one meetings and deals | Thousands of meetings and 100 plus deals reported across the programme | Deal quality varies and many pilot agreements remain conditional on clinical and regulatory milestones |
| Follow up support | EIC offers six months of follow up and Dealmaker Support | Six months is useful for scoping but longer timelines are typical for regulated healthcare pilots |
How startups can use EIC Business Acceleration Services
The Multi Corporate Day is provided under the EIC Corporate Partnership Programme which sits inside the EIC Business Acceleration Services. EIC awardees can access a range of tailored supports including matchmaking corporate days coaching investor readiness programmes and support for market expansion. For founders seeking corporate pilots the advice is the same as for any buyer facing engagement: show clear technical fit a realistic integration path regulatory understanding and a measurable value proposition that addresses the corporate's specific pain points.
For corporates the message is to commit resources to pilot design evaluation of safety and procurement readiness if they want to shorten time to value. Without clear internal adoption routes even well framed pilots can stall. The moderated format used at the Summit aimed to reduce that risk by involving both commercial and technical decision makers in the same room.
Bottom line
The EIC Summit Multi Corporate Day on Life Sciences concentrated relevant actors in one place and created a focused forum for early business development between Europe s deep tech start ups and major life science corporates. It demonstrates how curated preparation and direct access to corporate decision makers can accelerate the transition from scouting to scoping. The real test will be whether a meaningful share of these conversations convert into funded pilots clinical validation and commercial contracts. Observers should expect progress and some wins but also normal industry friction around regulation integration and long term procurement.